USPTO serial 79397582
ACTINEER
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 1, 2025
- Examiner
- FRENCH, CURTIS W
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ACTINEER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kari Moyer-Henry
Kari Moyer-Henry Lewis Kohn & Walker LLP17085 Via Del CampoSan Diego, CA 92127United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical substances, chemical materials and chemical preparations for use in the manufacture of medical products; chemical substances, chemical materials and chemical preparations for use in the manufacture of radiopharmaceutical products; chemical raw materials, in particular actinium-225 radiochemical, for the formulation of radiopharmaceutical products; chemical raw materials, in particular bismuth-213, for the formulation of radiopharmaceutical products | ACTIVE | — |
| 005 | Radiopharmaceutical diagnostic preparations for medical purposes; radiopharmaceutical diagnostic preparations for pharmaceutical purposes; radiopharmaceutical therapeutic preparations for medical purposes; radiopharmaceutical therapeutic preparations for pharmaceutical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy, positron emission tomography, single photon emission computed tomography, target radionuclide therapy and peptide receptor radionuclide therapy; radiopharmaceutical preparations, in particular actinium-containing radiopharmaceutical products in GMP quality; radiopharmaceutical preparations, in particular bismuth-containing radiopharmaceutical products in GMP quality; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular actinium-225; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular bismuth-213; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular actinium-225 for the treatment of tumour diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular bismuth-213 for the treatment of tumour diseases; target radiopharmaceuticals containing a target molecule, in particular peptide , depending on the indication, and a medical radioactive isotope; target radiopharmaceuticals containing a target molecule, in particular an antibody depending, on the indication, and a medical radioactive isotope; radiopharmaceuticals containing actinium-225 and its complexes; radiopharmaceuticals containing bismuth-213 and its complexes | ACTIVE | — |
| 010 | Medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, namely sample preparation devices automatically or manually operated in particular for the production of actinium-225 in GMP quality; medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, namely sample preparation devices automatically or manually operated in particular for the production of bismuth-213 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers, in particular devices containing fluidic processing components as valves, small vessels (5-500 ml) and purification columns for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of actinium-225 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular devices containing fluidic processing components as valves, small vessels (5-500 ml) and purification columns for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of bismuth-213 in GMP quality; radionuclide generator for radiopharmaceutical purpose | ACTIVE | — |
| 042 | Scientific and technological services and research relating to the use of actinium-225, in particular medical and pharmacological research services relating to the use of actinium-225; scientific and technological services and research relating to the use of bismuth-213, in particular medical and pharmacological research services relating to the use of bismuth-213; scientific and technological services and research relating to the use of other alpha emitters, in particular medical and pharmacological research services relating to the use of other alpha emitters | ACTIVE | — |
| 044 | Medical services, in particular medical services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies, namely intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and radionuclide therapy, peptide receptor radionuclide therapy, personal nuclear medicine and precision oncology; medical services for theranostics in the field of precision oncology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ITM Isotope Technologies Munich SE
- Other trademarks owned by ITM Isotope Technologies Munich SE
- Other trademarks owned by ITM Isotope Technologies Munich SE
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ACTINEER
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 30, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 12, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 12, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 31, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 15, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 14, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 2, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 1, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 1, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 11, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 11, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 5, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 21, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 30, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 30, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 30, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 18, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 18, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 18, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 18, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 18, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 30, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 11, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 11, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 9, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 8, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 2, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 20, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 20, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 13, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |